Sugi Predict

Sugi Predict / Compounds / SCHEMBL657872

SCHEMBL657872

SCHEMBL657872

O=C1Cc2ccc(Cl)nc2N1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AHR P35869 5/20 0.46
▸ CMA1 P23946 2/20 0.46
▸ PDE3B Q13370 1/20 0.42
▸ PDE3A Q14432 1/20 0.42
▸ TDP2 O95551 9/20 0.40
▸ CHEK1 O14757 1/20 0.40
▸ AURKA O14965 1/20 0.40
▸ DAPK3 O43293 1/20 0.40
▸ PRKD3 O94806 1/20 0.40
▸ MAP4K4 O95819 1/20 0.40
▸ ABL1 P00519 1/20 0.40
▸ NTRK1 P04629 1/20 0.40
▸ CSF1R P07333 1/20 0.40
▸ RET P07949 1/20 0.40
▸ MET P08581 1/20 0.40
▸ PDGFRB P09619 1/20 0.40
▸ PIM1 P11309 1/20 0.40
▸ FGFR1 P11362 1/20 0.40
▸ PDGFRA P16234 1/20 0.40
▸ FLT1 P17948 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30847568 1.00 AHR (0.46) AHRCMA1PDE3BPDE3ATDP2
SCHEMBL1233674 0.84 AHR (0.68) AHRCMA1PDE3BPDE3ATDP2
SCHEMBL5371747 0.83 PDE3B (0.43) PDE3BPDE3AIDH1
SCHEMBL31220098 0.77 AHR (0.46) AHRCMA1PDE3BPDE3ATDP2
SCHEMBL12680338 0.77 PDE3B (0.49) AHRCMA1PDE3BPDE3ATDP2
SCHEMBL1818417 0.75 RARB (0.35) AHRCMA1PDE3BPDE3ACHEK1
SCHEMBL18239104 0.73 PDE3B (0.42) AHRCMA1PDE3BPDE3ATDP2
SCHEMBL29827162 0.73 TDP2 (0.44) AHRCMA1PDE3BPDE3ATDP2
SCHEMBL19153232 0.73 PDE3B (0.42) AHRCMA1PDE3BPDE3ATDP2
SCHEMBL661744 0.72 KDR (0.42) AHRCMA1PDE3BPDE3ACHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12545685-B2 Dispiropyrrolidine derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2026-02-10 — — US disclosed
US-20240246989-A1 DISPIROPYRROLIDINE DERIVATIVES DAIICHI SANKYO COMPANY, LIMITED (JP) 2024-07-25 — — US disclosed
WO-2024064316-A1 COMPOUNDS AND COMPOSITIONS AS SMARCA2/4 INHIBITORS AND USES THEREOF REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2024-03-28 — — WO disclosed
CN-109745321-B Pharmaceutical composition comprising FGFR4 inhibitor 上海翰森生物医药科技有限公司 2022-04-29 — — CN disclosed
US-20220106324-A1 DISPIROPYRROLIDINE DERIVATIVES DAIICHI SANKYO COMPANY, LIMITED (JP) 2022-04-07 — — US disclosed
US-20220106324-A1 DISPIROPYRROLIDINE DERIVATIVES DAIICHI SANKYO COMPANY, LIMITED (JP) 2022-04-07 — — US disclosed
EP-2970119-B1 NOVEL INDOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS MERCK SHARP & DOHME (US) 2021-11-03 — — EP disclosed
EP-3527561-A1 NOVEL SUBSTITUTED PYRIMIDINE COMPOUNDS Grünenthal GmbH (DE) 2019-08-21 — — EP disclosed
EP-3527561-A1 NOVEL SUBSTITUTED PYRIMIDINE COMPOUNDS Grünenthal GmbH (DE) 2019-08-21 — — EP disclosed
US-10189854-B2 Substituted pyrimidine compounds GRUENENTHAL GMBH (DE) 2019-01-29 — — US disclosed
US-6498176-B1 INHIBITING TUMOR GROWTH VIA INHIBITION OF TUMOR-RELATED ANGIOGENESIS SMITHKLINEBEECHAM CORPORATION 2002-12-24 — — US disclosed
US-20020099071-A1 Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia GLENNON KIMBERLEY CAROLINE (US) 2002-07-25 — — US disclosed
US-6369086-B1 Substituted oxidole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors SMITHKLINE BEECHAM CORPORATION 2002-04-09 — — US disclosed
US-6350747-B1 PROTEIN SERINE/THREONINE KINASE AND PROTEIN TYROSINE KINASE ENZYME INHIBITORS; ANGIOGENESIS INHIBITORS; ANTITUMOR AND ANTIPROLIFERATIVE AGENTS GLAXO WELLCOME INC. 2002-02-26 — — US disclosed
EP-1165514-A1 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2002-01-02 — — EP disclosed
WO-2001077100-A2 BENZOAMIDE PIPERIDINE COMPOUNDS AS SUBSTANCE P ANTAGONISTS PFIZER PRODUCTS INC. (US) 2001-10-18 — — WO disclosed
US-6294532-B1 TREATMENT OF A NUMBER OF DISEASE STATES INCLUDING CANCER AND RHEUMATOID ARTHRITIS. ZENECA LIMITED (GB) 2001-09-25 — — US disclosed
WO-2000056710-A1 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2000-09-28 — — WO disclosed
EP-1005470-A1 OXINDOLYLQUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ZENECA LIMITED (GB) 2000-06-07 — — EP disclosed
WO-1999010349-A1 OXINDOLYLQUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ZENECA LIMITED (GB) 1999-03-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099071-A1 Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia PRKDC, PRKX, BMX AHR 2606/4885CMA1 3386/4885PDE3B 2169/4885
US-10189854-B2 Substituted pyrimidine compounds TYMP, PDE4A, DPYD AHR 3060/4885CMA1 460/4885PDE3B 17/4885
US-12545685-B2 Dispiropyrrolidine derivatives TP53, MDM2, TP53BP1 AHR 3275/4885CMA1 3900/4885PDE3B 4792/4885
US-20240246989-A1 DISPIROPYRROLIDINE DERIVATIVES MDM2, TP53, TP53BP1 AHR 2432/4885CMA1 2799/4885PDE3B 3667/4885
US-20220106324-A1 DISPIROPYRROLIDINE DERIVATIVES MDM2, TP53, TP53BP1 AHR 2432/4885CMA1 2799/4885PDE3B 3667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.